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Abstract
Introduction: The Intra-Aortic Balloon Pump (IABP) is frequently used to mechanically support the heart. There is
evidence that IABP improves microvascular flow during cardiogenic shock but its influence on the human
microcirculation in patients deemed ready for discontinuing IABP support has not yet been studied. Therefore we
used sidestream dark field imaging (SDF) to test our hypothesis that human microcirculation remains unaltered
with or without IABP support in patients clinically ready for discontinuation of mechanical support.
Methods: We studied 15 ICU patients on IABP therapy. Measurements were performed after the clinical decision
was made to remove the balloon catheter. We recorded global hemodynamic parameters and performed venous
oximetry during maximal IABP support (1:1) and 10 minutes after temporarily stopping the IABP therapy. At both
time points, we also recorded video clips of the sublingual microcirculation. From these we determined indices of
microvascular perfusion including perfused vessel density (PVD) and microvascular flow index (MFI).
Results: Ceasing IABP support lowered mean arterial pressure (74 ± 8 to 71 ± 10 mmHg; P = 0.048) and increased
diastolic pressure (43 ± 10 to 53 ± 9 mmHg; P = 0.0002). However, at the level of the microcirculation we found an
increase of PVD of small vessels <20 μm (5.47 ± 1.76 to 6.63 ± 1.90; P = 0.0039). PVD for vessels >20 μm and MFI for
both small and large vessels were unaltered. During the procedure global oxygenation parameters (ScvO2/SvO2)
remained unchanged.
Conclusions: In patients deemed ready for discontinuing IABP support according to current practice, SDF imaging
showed an increase of microcirculatory flow of small vessels after ceasing IABP therapy. This observation may
indicate that IABP impairs microvascular perfusion in recovered patients, although this warrants confirmation.
Introduction
In cardiogenic shock, intra-aortic balloon counterpulsa-
tion is frequently used to mechanically support the fail-
ing heart [1,2]. Intra-Aortic Balloon Pump- (IABP-)
support improves coronary blood flow by augmenting
systemic and coronary diastolic blood pressure and
increases cardiac index by reducing left ventricular work
[1,3]. As a bridge to recovery, its goal is to facilitate the
heart and continuously provide adequate systemic
perfusion.
However, the microcirculation is ultimately responsible
for delivering oxygen and substrates to tissue [4]. The
recent emergence of Orthogonal Polarization Spectral
imaging and its successor sidestream dark field imaging
(SDF) has enabled imaging of the human microcircula-
tion in real time [5-7]. These techniques have been used
to characterize the microcirculation in various clinical
situations including cardiogenic shock.
For example, De Backer et al. [ 8 ]d e m o n s t r a t e dt h a t
microvascular blood flow worsens in severe cardiac failure
and cardiogenic shock and is associated with in-hospital
mortality. Importantly, there is now a large body of evi-
dence that microvascular flow may be relatively indepen-
dent from global hemodynamics [4]. For example, arterial
and venous blood pressure, cardiac output as well as cen-
tral or mixed venous oxygen saturation may not necessa-
rily reflect microvascular perfusion [9-14]. However, in
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parameters frequently guide the decision when to start
and withdraw IABP-therapy.
Three recent trials examined the microcirculatory
effects of counterpulsation during cardiogenic shock and
high risk percutaneous coronary intervention (PCI)
[15-17]. Two of these reported IABP-induced improve-
ment in microvascular flow whereas the other did not.
Therefore our understanding of microvascular perfusion
during IABP-support remains based on limited and con-
flicting data. This paucity of data is even more apparent
in deciding when to best withdraw IABP-support. No
previous study has addressed this issue. To examine the
influence of IABP-support on microcirculation of recov-
ered patients, we studied patients deemed ready for dis-
continuing IABP-support as judged by their treating
physicians. We used SDF-imaging to test our hypothesis
that microvascular flow is unaltered with or without
IABP-support in this clinical setting.
Materials and methods
The local institutional review board approved the study
protocol. Since the study was observational and given
the non-invasive nature of SDF-imaging, the need for a
written informed consent was waived in accordance
with the national Law on Experiments with Humans.
The study was performed at the intensive care unit
(ICU) of a large teaching hospital between April 2007
and October 2008.
We included adult patients that had an IABP in place.
Patients were only included if and when the responsible
ICU physician had made the decision that the subjects
were clinically ready for discontinuation of IABP-sup-
p o r t .W ee x c l u d e dp a t i e n t st h a ts h o w e ds i g n so fs e p s i s
(suspected or proven systemic infection with ≥2 severe
inflammatory response syndrome (SIRS) criteria: tachy-
cardia >90 beats/minute and/or tachypnoea >20 breaths/
minute or arterial pCO2 < 32 mmHg/4,2kPa and/or
body temperature >38°C or <36°C and/or WBC count
>12,000 cells/mm
3 or <4,000 cells/mm
3 or >10% imma-
ture cells). Disruption or laceration of the oral floor
mucosa was an exclusion criterion because this would
interfere with microcirculatory imaging. As per clinical
routine, all patients underwent continuous invasive
monitoring of arterial and central venous blood pressure
and some patients had a surgically placed pulmonary
artery catheter.
A Datascope® CS300 intra aortic balloon pump system
(Datascope Corporation, Mahwah, NJ, USA) was used in
all studied patients. The IABP system was set automati-
cally, using the electrocardiogram for optimal timing so
that inflation and deflation occurred at the dicrotic
notch and immediately before systolic upstroke, respec-
tively. Optimal balloon size was chosen depending on
patient height before insertion. Routine chest X-rays
were examined to define correct intra-aortic placement
of the IABP balloon, 2 to 3 cm distal to the origin of
the left subclavian artery. All hemodynamic parameters
were recorded continuously by our patient data manage-
ment system.
The decision to discontinue IABP-support was a clini-
cal one and left completely at the discretion of the ICU-
team. In most cases, this included a weaning trial in
which the IABP-assist ratio was lowered step by step
over several hours. Possible changes in routinely mea-
sured macrocirculatory and laboratory parameters were
observed during this process.
Microcirculatory measurements were performed using
SDF imaging, which has been described in detail else-
where [7]. In brief, it consists of a handheld video
microscope that emits stroboscopic green light (530 nm)
from an outer ring at the tip of the probe. This light is
absorbed by haemoglobin. A negative image of moving
red blood cells is sent back through the isolated optical
core of the probe toward a charge-coupled device
(CCD) camera. SDF imaging has been shown to provide
ah i g h e ri m a g i n gq u a l i t yw i t hm o r ed e t a i la n dl e s s
motion blur than its predecessor Orthogonal Polariza-
tion Spectral (Ops) imaging [7]. A typical example of a
SDF-image is shown in Figure 1.
Within two hours after the decision to discontinue
IABP-support had been made, we performed SDF ima-
ging at two points in time. First, the IABP device was
set to a 1:1 assist ratio, if this was not already the
selected mode. After 10 minutes, to allow for a new
steady state to occur, the first series of microvascular
recordings was made. Next, the IABP device was tem-
porarily stopped. After another 10 minutes, we recorded
a second series of SDF video clips. At both measuring
points, venous and arterial blood gas analyses were col-
lected. In patients with a pulmonary artery catheter
mixed venous saturation (SvO2) was determined, other-
wise central venous saturation (ScvO2) was measured.
Figure 1 A screenshot from a typical example of the human
sublingual microcirculation using SDF imaging.
Munsterman et al. Critical Care 2010, 14:R161
http://ccforum.com/content/14/4/R161
Page 2 of 7After the procedure the IABP device was switched back
on at the pre-measurement settings. During the proce-
dure dosages of continuous intravenous drugs were
recorded and no dosing adjustments were made.
In a recent round table conference, international
experts reached consensus on how to best evaluate the
microcirculation using OPS and SDF imaging [18]. We
implemented all recommendations given in this confer-
ence. Video clips were immediately saved as digital AVI-
DV files to a hard drive of a personal computer using an
analogue-to-digital converter (Canopus, Kobe, Japan) and
t h ef r e e w a r ep r o g r a mW i n D V[ 1 9 ] .W eu s e d5 ×o p t i c a l
magnification, producing images representing approxi-
mately 940 × 750 mm
2 of tissue surface. Per measuring
point, clips at three sublingual sites yielding at least
20 seconds of stable video per site were recorded. Special
care was taken to avoid pressure artefacts, adhering to
the standard operating procedure previously described by
Trzeciak et al. [20] and recommended in the round table
conference [18]. In brief, secretions were removed with
gauze, and, after obtaining good imaging focus, the probe
was pulled back gently until contact was lost and then
advanced again slowly to the point at which contact was
regained. The authors paid special attention to the larger
vessels at the time of recording because alterations in
their flow with probe manipulation may indicate pressure
artefacts.
One video file was recorded for each location at each
measuring point. These were stored under a random num-
ber. At a later time, these were analyzed by one of the
authors (PWGE) using the AVA 3.0 software program
(Microvision Medical, Amsterdam, The Netherlands).
According to the recommendations, microvascular flow
index (MFI), perfused vessel density (PVD), proportion of
perfused vessels (PPVs), and indices of heterogeneity were
determined for every patient at both time points. All have
been validated previously [20-22]. As published recently,
each score was determined for both large and small micro-
vessels, with a cut-off diameter of 20 μm [23]. In addition,
the authors defined large-type vessels that split into other
vessels as arterioles. Other large vessels were defined as
venules.
For PPV and PVD, vessel density was calculated as the
number of vessels crossing three horizontal and three
vertical equidistant lines spanning the screen divided by
the total length of the lines. Perfusion at each crossing
was then scored semi-quantitatively by the eye as follows:
0 = no flow (no flow present for the entire duration of
the clip), 1 = intermittent flow (flow present <50% of the
duration of the clip), 2 = sluggish flow (flow present
>50% but <100% of the duration of the clip or very slow
flow for the entire duration of the clip), and 3 = continu-
ous flow (flow present for the entire duration of the clip).
PVD was then calculated as the number of crossings with
flow scores greater than 1. PPV was calculated as the pro-
portion of crossings with flow scores greater than 1
divided by the total number of crossings. For each mea-
suring point and each patient, the scores for PPV and
PVD were averaged. PVD is expressed in n/mm, whereas
PPV is expressed as a percentage. Intra-observer variabil-
ity ranges between 2.5% and 4.7% for PPV and between
0.9% and 4.5% for PPV. The inter-observer variability is
slightly higher: between 3.0% and 6.2% and between 4.1%
and 10%, respectively [21].
MFI was based on the determination of the predomi-
nant type of flow in four quadrants adhering to the
same scoring system. MFI is the sum of these flow
scores divided by the number of quadrants in which the
vessel type is visible. The intra-observer agreement of
MFI is about 85% (kappa score = 0.78) and inter-obser-
ver agreement about 90% (kappa score = 0.85) [22]. For
each measuring point and each patient, the scores for
MFI were averaged.
Heterogeneity was assessed in two different ways. For
PVD, the coefficient of variation was determined. For
MFI, the authors assessed heterogeneity in each patient
by subtracting the lowest from the highest quadrant
MFI and dividing the result by the mean MFI [20,21].
We used Wilcoxon matched pairs tests for MFI and
paired t tests for other data. We used Spearman tests to
detect correlation between global and microvascular
parameters. Results are reported as median and inter-
quartile ranges (IQR) for MFI and as the mean ± stan-
dard deviation (SD) for other parameters, unless
indicated otherwise. The study was powered to detect a
minimum of 15% difference in small-vessel PVD after
switching off the IABP with a =0 . 0 5a n d1 - b = 0.80.
Based on previous studies by others and us [8,10,21]
this showed the need for inclusion of 14 patients.
Results
Patients
We included 15 patients. Baseline characteristics of the
study population, including risk factors for cardiovascu-
lar disease and continuous intravenous dosage of
vasoactive drugs, are shown in Table 1. All participants
were admitted at the intensive care unit of St. Antonius
Hospital, Nieuwegein, The Netherlands.
Mean APACHE (acute physiology and chronic health
evaluation scoring system) II score 24 hours after admis-
sion at the ICU was 14.5 ± 5.3. Indications for IABP
placement were urgent coronary artery bypass grafting
d u et ou n s t a b l ea n g i n ap e c t o r i sw i t hs e v e r ec o r o n a r y
disease (n = 6, 40.0%), cardiogenic shock due to myocar-
dial infarction without heart surgery (n = 2, 13.3%), car-
diogenic shock after heart surgery (n = 2, 13.3%), due to
acute prosthetic aortic valve displacement after surgery
(n = 1, 6.7%) or after cardiac arrest with or without
Munsterman et al. Critical Care 2010, 14:R161
http://ccforum.com/content/14/4/R161
Page 3 of 7percutaneous coronary intervention (n = 4, 26.6%).
Mean duration of IABP-therapy at the time of measure-
ment was three days (range one to five days). During
the experiment, six patients had a pulmonary artery
catheter in place and 11 patients were mechanically
ventilated.
Systemic hemodynamic data
Table 2 depicts the differences in global hemodynamic
parameters between the two points of interest. The
institution of IABP-support significantly increased mean
arterial pressure (MAP). However, recorded diastolic
blood pressure was significantly lower. It is important to
point out that this represents the lowest pressure
recorded during the cardiac cycle, which is the purpose
of balloon counterpulsation. After switching off IABP-
support no differences in venous oxygen saturation
occurred (ScvO2/SvO2; 70.9% ± 7.2 vs. 71.4% ± 7.5;
P = 0.897).
Microcirculation
The authors successfully obtained high-quality images in
each patient. In total 90 video clips were recorded.
Results are shown in Table 3. PVD of small vessels
(< 20 μm) was significantly lower during IABP-support;
5.47 ± 1.76 vs. 6.63 ± 1.90; P = 0.0039 (Figure 2). Other
microcirculatory parameters were not significantly
altered.
The relationship between changes in mean arterial
pressure, diastolic arterial pressure and S(c)vO2 versus
changes in PVD in individual patients comparing max-
imal support vs. no support was determined. Spearman
tests did not show a statistically significant correlation
for any of these global hemodynamic parameters (r =
-0.1; P = 0.71, r = 0.1; P = 0.72, r = 0.1; P =0 . 6 9
respectively). In addition, no correlation was found
between small vessel PVD and APACHE II score
(r = 0.04; P = 0.88).
Discussion
To the best of our knowledge, this is the first study to
report on the microvascular effects of IABP switch-off
in recovered patients deemed ready for IABP removal.
Our most prominent finding is that cessation of IABP-
support resulted in a significant and paradoxical
increase in small-vessel PVD, independent from initial
disease severity. This is in contrast with the loss of
IABP-induced raise of mean arterial pressure in these
patients [1-3] and, perhaps more importantly, in con-
trast with SvO2 or ScvO2 values, which remained
Table 1 Patient characteristics and drugs
Mean ± SD or n (%)
Number of patients 15
Age (years) 65.7 ± 11.8
Male 12 (80)
Length (cm) 175 ± 11
Weight (kg) 81 ± 14
Hemoglobin level (μmol) 6.2 ± 0.7
Hematocrit (%) 30 ± 3.5
Arterial blood lactate (mmol/l)* 1.2 ± 0.4
Temperature (°C) 36.9 ± 1.0
APACHE II score 14.5 ± 5.3
History of vascular disease 5 (33)
Hypertension 6 (40)
Diabetes Mellitus 3 (20)
Chronic renal insufficiency 1 (7)
Dopamine (mg/h), nine patients 17.7 ± 8.7
Norepinephrine (mg/h), five patients 0.26 ± 0.2
Dobutamine (mg/h), two patients 15.0 ± 7.1
Nitroglycerine (mg/h), six patients 1.0 ± 0.0
Artificial ventilation 11 (73)
Values are the number of patients, with percentages in parentheses.
Catecholamine and vasopressors doses represent those used during SDF
imaging. Other figures are mean ± standard deviation. *, When measured, 11
patients; APACHE II, acute physiology and chronic health evaluation scoring
system II; SDF, sidestream dark field imaging
Table 2 Global hemodynamic data
Assist ratio 1:1 No assist Difference 95% CI lower boundary 95% CI upper boundary P-value
Heart rate (beats/minute) 83.4(12.1) 85.1(12.8) -1.7 -4.45 0.98 0.193
ABP systolic (mmHg) 115.3 (16.0) 110.3 (15.0) 5.0 -2.18 12.18 0.157
ABP mean (mmHg) 73.7 (8.2) 70.7 (10.0) 2.9 0.03 5.83 0.048
ABP diastolic (mmHg) 42.6 (10.0) 53.3 (8.8) -10.7 -15.20 -6.10 0.0002
CVP (mmHg) 12.5 (6.0) 13.0 (6.6) -0.5 -1.72 0.78 0.437
ScvO2/SvO2 (%) 70.9 (7.2) 71.4 (7.5) -0.5 -1.48 1.31 0.897
SpO2 (%) 96.4 (2.3) 96.5 (2.1) -0.1 -0.91 0.65 0.719
PAP systolic (mmHg) 46.0 (8.3) 46.3 (6.8) -0.3 -2.78 2.12 0.741
PAP mean (mmHg) 28.8 (4.2) 28.5 (4.3) 0.3 -0.75 1.41 0.465
PAP diastolic (mmHg) 22.7 (8.1) 22.5 (7.8) 0.2 -0.62 0.95 0.61
Data are presented as mean ± standard deviation in parentheses. ABP, mean arterial pressure; CI, confidence interval; CVP, central venous pressure; PAP,
pulmonary artery pressure; ScvO2/ScvO2, central venous/mixed venous oxygen saturation; SpO2, peripheral oxygen saturation.
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adds to the large body of evidence that global hemody-
namic parameters and venous oximetry do not necessa-
rily reflect microvascular perfusion [4,9,10,21,22]. It is
the first time that such a discrepancy is demonstrated
after withdrawal of IABP-support.
Three recent studies examined the effects of IABP on
human microcirculation [15-17]. Jung et al. included 13
patients with cardiogenic shock after acute myocardial
infarction. The authors recorded SDF video images
before and shortly after the IABP-support was tempora-
rily stopped. MFI of small and medium vessels (10 to 50
μm) was significantly higher in patients with IABP-sup-
port [15]. In contrast, den Uil et al. studied a heteroge-
neous group of 13 patients suffering from cardiogenic
shock of variable severity and found no differences in
perfused capillary density (PCD) and red blood cell velo-
city [16]. This was despite the fact that mean arterial
pressure and cardiac index were significantly lower after
the IABP-assist ratio was switched from 1:1 to 1:8.
Finally, more recently, Jung et al. studied six patients
immediately following high-risk PCI. MFI of both small
and large vessels decreased significantly immediately
after a short period of IABP-support discontinuation
and returned to baseline after restarting therapy. Again,
no correlation with global hemodynamic parameters was
found [17].
Both groups chose not to fully incorporate recent
recommendations regarding image acquisition or report-
ing standard microvascular flow parameters [18]. This
hampers direct comparison with our study. More impor-
tantly, our population of recovered patients is markedly
different. However, this does not dismiss our sharply
contrasting finding of improved PVD after IABP switch-
off. It is plausible that IABP has different microvascular
effects at different stages of disease and recovery.
Although speculative, one possible explanation for the
observed difference in microvascular perfusion could be
a mechanical effect of IABP. The pressure decrease
induced by balloon deflation during diastole could cre-
ate a collapse of certain parts of capillary microcircula-
tion. This effect is consistent with the concept of
vascular waterfalls: the flow in front of a waterfall is not
affected by its height. This analogy explains why some-
times global and regional blood flow ceases at positive
arterial pressures well above venous pressure [24,25].
Interestingly, an IABP-induced transient blood flow
reversal in basal cerebral arteries has been reported pre-
viously [26,27], which is consistent with this theory.
However, correlation between the difference in diastolic
pressure and the difference in PVD between the study
time points did not reach statistical significance. Con-
versely, this may not invalidate our hypothesis, as
Table 3 Microcirculation
Assist ratio 1:1 No assist Difference 95% CI lower boundary 95% CI upper boundary P-value
PVD vessels <20 μm (mm
-1) 5.47 (1.76) 6.63 (1.90) -1,16 -1.89 -0.44 0.0039
PPV vessels <20 μm (mm
-1) 88.4 (14.1) 88.8 (16.4) -0,43 -6.49 5.61 0.879
MFI vessels <20 μm 2.75 [2.0 to 3.0] 3.0 [2.58 to 3.0] -0.25 NA NA 0.422
HI-PVD vessels <20 μm 0.38 (0.23) 0.40 (0.37) -0,02 -0.19 0.15 0.834
HI-MFI vessels <20 μm 0.68 (0.68) 0.57 (0.87) 0,11 -0.27 0.49 0.547
PVD vessels >20 μm (mm
-1) 1.34 (0.88) 1.64 (0.63) -0,31 -0.83 0.21 0.222
PPV vessels >20 μm (mm
-1) 95.5 (9.6) 96.9 (7.7) -1,38 -4.94 2.18 0.420
MFI vessels >20 μm 3.0 [2.5 to 3.0] 3.0 [2.78 to 3.0] 0 NA NA 0.109
HI-PVD vessels >20 μm 0.59 (0.25) 0.50 (0.25) 0,08 -0.08 0.25 0.299
HI-MFI vessels >20 μm 0.44 (0.58) 0.18 (0.29) 0,26 -0.05 0.57 0.096
MFI is reported as median with interquartile ranges in square brackets. Other microcirculatory parameters are mean values ± standard deviation in parentheses.
CI, confidence interval; HI, heterogeneity index; MFI, microvascular flow index; NA, not applicable; PPV, percentage of perfused vessels; PVD, perfused vessel
density.
Figure 2 The effect of IABP on perfused vessel density (PVD)
for vessels <20 μm. The perfused vessel density increased
significantly, 5.47 ± 1.76 to 6.63 ± 1.90 (P = 0.0039), 10 minutes after
IABP switch-off.
Munsterman et al. Critical Care 2010, 14:R161
http://ccforum.com/content/14/4/R161
Page 5 of 7microvascular de-recruitment is probably an all or noth-
ing stochastic process.
There are several important limitations to our study.
First, we did not routinely measure cardiac output.
However, this is highly representative of current prac-
tice. In addition, it may be reasonable to assume that
cardiac output remained constant as no changes in
venous oximetry and heart rate were observed and no
drug dosing adjustments were made during the study
period. Interestingly, if IABP would have increased car-
diac output in our patients, as it has been reported to
do so in other clinical situations, this would perhaps
even strengthen our findings. This would mean that
despite increased cardiac output during IABP-support,
microvascular flow would be relatively impaired as com-
pared to no IABP-support.
Second, we chose the sublingual site for its proximity
to the brain, ease of access and its philogenetic relation-
ship to the gut. There is conflicting data on whether
sublingual microvascular perfusion represents other vas-
cular beds [28,29]. Interestingly, a recent animal study
shows that in the setting of resuscitation, cerebral
microcirculation is relatively protected as compared to
sublingual microvascular perfusion [30]. If applicable to
the setting studied by us, this would imply that cerebral
microvascular perfusion improves to a greater extent
after IABP switch-off. Third, the fact that our findings
could possibly be explained by temporal changes in
microcirculation instead of IABP cannot be ruled out
because we did not perform a final measurement after
reinstituting IABP-support. Finally, but perhaps most
important, a heterogeneous group was studied in which
a minority initially had cardiogenic shock. However, no
correlation of initial disease severity (APACHE II score)
and microcirculatory perfusion at the time of measure-
ment could be found. Further, there were no differences
in microcirculatory perfusion between patients with
initial shock and those without shock. The absence of
correlation between microvascular flow and APACHE II
and shock state may not be surprising as patients were
only studied during a phase in which they were deemed
ready for discontinuation of IABP-support.
Given these limitations, our findings and their clinical
consequences should be interpreted with caution. In
addition, while we have shown that IABP may impair
tissue perfusion in hemodynamically recovered patients,
we did not observe signs of cell ischemia (for example,
lactate acidosis) nor signs of progressive organ dysfunc-
tion during IABP-therapy on the day measurements
were performed. In addition PVD values during IABP-
support are similar to those found in healthy controls
by De Backer [8] and to those found after routine car-
diac surgery by us [10].
However, given the current controversy on the evi-
dence of IABP-support and therefore its indication [31],
coupled with complication risks [32], it may be prudent
not to ignore our results. Perhaps the best strategy is to
optimize the duration of support and our findings could
possibly be the consequence of the fact that our patients
may have been too long IABP-treated. This could
explain our findings. The role of microvascular imaging
to achieve this goal merits further study.
Conclusions
The results of this study show that cessation of IABP-
support resulted in a paradoxical increase of microvas-
cular flow in small vessels at a time clinicians deemed
IABP was no longer necessary. These changes are inde-
pendent from global hemodynamic parameters and oxy-
gen derived variables.
Clinicians that routinely rely on these parameters for
their decision-making should again be reminded that
these do not necessarily reflect microvascular perfusion
in a wide range of clinical settings including that of ces-
sation of IABP-support.
Key messages
￿ Discontinuing IABP-therapy increases sublingual
microvascular perfusion of small vessels in patients
deemed clinically ready for ceasing IABP-support.
￿ Global hemodynamic parameters and venous oxi-
metry do not correlate with and may therefore be
unreliable for predicting adequacy of microvascular
perfusion in this clinical setting.
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